chevron_leftBack
As of 24 April 2025, Biosynex S.A. has a market cap of $29.87M USD, ranking #27648 globally and #386 in France. It ranks #2780 in the Healthcare sector, and #345 in the Medical Devices industry.
Key Stats
Market Cap
$29.87MUSD
26.25M EUR
Enterprise Value
$88.96MUSD
78.5M EUR
Revenue (TTM)
$118.42MUSD
104.07M EUR
EBITDA (TTM)
-$22.93MUSD
-20.24M EUR
Net Income (TTM)
-$43.79MUSD
-38.48M EUR
EBITDA Margin
-19%
Profit Margin
-37%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Larry Abensur
open_in_new
Employees
569
Founded
1993
Website
biosynex.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.7% | -3.4% | -11% | -2% | -50% | -69% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ALBIO
Biosynex SA
ISIN: FR0011005933
Shares Out.:
Shares Outstanding:
18.19M1
Shares Float:
7.897M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.38 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Biosynex S.A.
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
